GlassScriptPhysician profile
James F Smith
NPI 1881684256
$30,604.73
in general payments reported to CMS, 2019-2025
41 companies · $1,671 in 2025
The $1,671 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $6,076 · 2021: $910 · 2022: $1,582 · 2023: $973 · 2024: $1,454 · 2025: $1,671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,099.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,098.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $11,783.15 | 2019-2025 | General - Vascular Access, Avvigo Guidance System, Carotid Wallstent |
| Sanofi-Aventis U.S. LLC | $8,298.14 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $2,409.65 | 2019-2025 | Evkeeza |
| Silk Road Medical, INC. | $1,944.92 | 2019-2023 | Enroute Transcarotid Stent, Enroute Transcarotid Neuroprotection System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $896.79 | 2019-2025 | Lifevest |
| Abiomed | $889.15 | 2019-2025 | Impella |
| Medtronic, INC. | $510.24 | 2022-2025 | Ffrangio, Micra, Onyx Frontier |
| Stryker Corporation | $310.89 | 2025 | Artix Mt, Flowtriever, Ct Thrombectomy System Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $294.24 | 2019-2025 | Jardiance |
| Heartflow, INC. | $275.86 | 2019-2021 | |
| Amgen INC. | $257.69 | 2019-2024 | Repatha |
| Esperion Therapeutics, INC. | $221.16 | 2021-2025 | Nexletol |
| Penumbra, INC. | $205.74 | 2019-2024 | Indigo System |
| Abbott Laboratories | $205.58 | 2019-2025 | Xience Skypoint |
| Medtronic Vascular, INC. | $195.30 | 2019-2020 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $187.32 | 2019-2025 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $185.77 | 2019-2025 | Farxiga, Lokelma |
| Novartis Pharmaceuticals Corporation | $172.00 | 2023-2025 | |
| Cardiovascular Systems INC. | $161.65 | 2019-2022 | |
| Pfizer INC. | $142.45 | 2019-2025 | |
| Edwards Lifesciences Corporation | $120.69 | 2019 | |
| Daiichi Sankyo INC. | $113.49 | 2022-2024 | Injectafer |
| Kestra Medical Technology Services, INC. | $113.46 | 2025 | Assure Wcd |
| Janssen Pharmaceuticals, INC | $111.21 | 2022-2024 | Xarelto |
| Atricure, INC. | $91.48 | 2019-2025 | Atriclip Laa Exclusion System, Synergy Ablation System |
| Philips North America LLC | $82.04 | 2019-2025 | Ecc Solutions |
| Shockwave Medical, INC | $67.70 | 2022 | |
| Inspire Medical Systems, INC. | $46.91 | 2025 | Inspire |
| Itamar Medical INC | $40.55 | 2023-2025 | Watchpatone |
| Bayer Healthcare Pharmaceuticals INC. | $40.35 | 2025 | |
| Novo Nordisk INC | $36.78 | 2024 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $36.17 | 2024 | Verquvo |
| Chiesi USA, INC. | $33.27 | 2022 | |
| Lilly USA, LLC | $18.61 | 2025 | Mounjaro, Zepbound |
| Kiniksa Pharmaceuticals, LTD. | $18.48 | 2023 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $17.78 | 2025 | Amvuttra |
| Siemens Medical Solutions USA, INC. | $14.33 | 2020 | |
| Gilead Sciences, INC. | $13.78 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $13.56 | 2024 | Arcalyst |
| Terumo Medical Corporation | $13.48 | 2020 | |
| Cardiva Medical, INC. | $12.92 | 2023 | Cardiva Vascade Mvp Vvcs 6-12f |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.